Dinash Yanamadula, MD
Interventional Pain Medicine · Lawrenceville, NJNPI 1578507893
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,953 of the $16,142 with a category attached, or 67.9%. 34 manufacturers reported payments, led by Abbott at 45.1% of the total. Reporting peaked in 2023 at $4,722 and has fallen 71.1% since, to $1,365 in 2025.
Across 563 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Averitas Pharma Inc.$4K
- Globus Medical$837
- Nevro Corp.$767
- Collegium Pharmaceutical, Inc.$670
- Biodelivery Sciences International, Inc.$491
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$3,50022%
- Travel & lodging$1,64410%
- Food & beverage$10,95368%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 277 | $7,281 |
| Averitas Pharma Inc. | 2 | $3,521 |
| Globus Medical | 18 | $837 |
| Nevro Corp. | 25 | $767 |
| Collegium Pharmaceutical, Inc. | 45 | $670 |
| Biodelivery Sciences International, Inc. | 46 | $491 |
| Si-bone, Inc. | 14 | $473 |
| Hikma Pharmaceuticals USA | 20 | $278 |
| Kowa Pharmaceuticals America, Inc. | 21 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $187 |
| Nalu Medical, Inc. | 2 | $181 |
| GRT US Holding, Inc. | 12 | $140 |
| Boston Scientific | 8 | $139 |
| Almatica Pharma LLC | 10 | $134 |
| Zimmer Biomet | 3 | $94 |
| Saluda Medical Americas, Inc. | 2 | $68 |
| Protega Pharmaceutials Inc | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 5 | $63 |
| Fidia Pharma USA Inc. | 5 | $63 |
| Pacira Therapeutics, Inc. | 4 | $61 |
| Pfizer | 4 | $56 |
| Johnson & Johnson | 3 | $47 |
| GSK | 3 | $46 |
| Forte Bio-pharma LLC | 2 | $35 |
| Lilly USA, LLC | 3 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Amgen | 2 | $26 |
| Bioventus LLC | 1 | $24 |
| Revance Therapeutics, Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Vertex | 1 | $16 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$3,500
- PROCLAIM$2,490
- Senza$485
- iFuse Implant$259
- Proclaim IPG$225
- Lamitrode SCS Leads$137
- Proclaim Family of SCS IPGs$125
- Axium$118
- Omnia$105
- Prodigy Family of SCS IPGs$105
- Nalu Neurostimulation System$101
How this compares
$16,142 in reported general payments places this provider in the 85th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 113 | $84,857 |
| Nucynta ErTapentadol Hcl | 25 | $26,971 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 301 | $8,661 |
| Fentanyl | 54 | $8,303 |
| Oxycodone Hcl | 392 | $8,288 |
| SymproicNaldemedine Tosylate | 14 | $6,292 |
| Buprenorphine | 26 | $4,124 |
| Morphine Sulfate ErMorphine Sulfate | 101 | $3,458 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 130 | $3,383 |
| Lidocaine | 14 | $2,374 |
| Diclofenac Sodium | 23 | $2,245 |
| KloxxadoNaloxone Hcl | 13 | $1,539 |
| Hydromorphone Hcl | 48 | $1,491 |
| Gabapentin | 115 | $1,328 |
| EndocetOxycodone Hcl/Acetaminophen | 18 | $991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er | $670 | $26,97125 claims |
| Hikma Pharmaceuticals USABuprenorphine, Kloxxado, Morphine Sulfate | $278 | $6,64362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 interventional pain medicine providers in New Jersey.
Other interventional pain medicine in Lawrenceville
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
- Jay ShahColonia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.